Residency · Residency · Urology

Overactive Bladder: Diagnosis and Pharmacotherapy

Definition

Overactive bladder (OAB) is characterized by urgency, with or without urgency urinary incontinence, usually accompanied by increased frequency and nocturia, in the absence of urinary tract infection or other obvious pathology, according to the International Continence Society (ICS) definition. OAB can be classified into two subtypes: OAB-dry, which involves urgency and frequency without incontinence and accounts for approximately two-thirds of patients, and OAB-wet, which includes urgency accompanied by urgency urinary incontinence, representing about one-third of cases. It is important to recognize that OAB is a symptom-based clinical diagnosis rather than a urodynamic diagnosis. Detrusor overactivity (DO), defined as involuntary detrusor contractions during bladder filling observed on urodynamics, may or may not be present in patients with OAB.

Epidemiology

OAB affects approximately 12-17% of adults, with prevalence increasing with age. It affects men and women equally, although men are often underdiagnosed. In men, OAB symptoms frequently coexist with benign prostatic hyperplasia (BPH) or bladder outlet obstruction (BOO), necessitating careful distinction between storage symptoms (urgency, frequency) and voiding symptoms (hesitancy, weak stream). OAB significantly impacts quality of life, contributing to social isolation, depression, increased risk of falls related to nocturia, skin breakdown, and caregiver burden. The economic burden is substantial, costing billions annually due to expenses related to incontinence pads, laundry, and healthcare visits.

Pathophysiology

The pathophysiology of OAB is multifactorial and not fully understood. The myogenic theory proposes that altered properties of detrusor smooth muscle, including increased gap junctions, lead to coordinated spontaneous contractions. The neurogenic theory suggests impaired central and peripheral inhibition of the micturition reflex, with upregulation of afferent C-fibers contributing to heightened bladder sensation. The urothelial/suburothelial theory posits that the urothelium releases mediators such as ATP and acetylcholine that activate suburothelial afferent nerves. The integrative hypothesis combines these mechanisms to explain OAB. In men, BPH or BOO can cause secondary detrusor changes including hypertrophy, denervation, and fibrosis, which further contribute to symptoms.

<image>Diagram illustrating the neurophysiology of the micturition reflex and sites of dysfunction in OAB, including afferent C-fiber upregulation and detrusor smooth muscle changes</image>

Evaluation

History

A thorough history is essential to characterize symptoms, focusing on urgency, which is the cardinal symptom, frequency defined as more than eight voids per 24 hours, nocturia with at least one episode per night, and urgency incontinence. The onset, duration, severity, and degree of bother should be assessed. Fluid intake patterns, including caffeine, alcohol, total volume, and timing, must be reviewed. Medication history is important, particularly diuretics, cholinesterase inhibitors, and lithium, which can exacerbate symptoms. Neurologic history should be explored for conditions such as stroke, multiple sclerosis, Parkinson’s disease, spinal cord disease, and diabetes. Prior pelvic or prostate surgery and bowel function, especially constipation which can worsen OAB, should also be evaluated.

Voiding Diary

A voiding diary maintained for at least three days is invaluable. Patients record voiding times, volumes, episodes of leakage, and fluid intake. This diary establishes baseline frequency, functional bladder capacity, and nocturia patterns, while also identifying modifiable factors such as excessive fluid intake or caffeine consumption.

Physical Examination

Physical examination includes abdominal assessment for a distended bladder suggestive of retention. In women, pelvic examination evaluates for prolapse and vaginal atrophy. In men, digital rectal examination assesses prostate size and consistency. Neurologic examination focuses on perineal sensation (S2-S4), anal tone, and the bulbocavernosus reflex to detect neurologic deficits.

Laboratory

Urinalysis is performed to rule out urinary tract infection, hematuria, or glucosuria. Post-void residual (PVR) volume measurement helps exclude overflow incontinence or incomplete bladder emptying; an elevated PVR suggests bladder outlet obstruction or detrusor underactivity. Prostate-specific antigen (PSA) testing may be indicated in men if BPH or prostate cancer is suspected.

Urodynamics

Urodynamic studies are not required for the initial diagnosis of OAB, which is clinical. They are indicated when the diagnosis is uncertain, empiric therapy has failed, neurogenic bladder is suspected, before invasive or third-line therapies, or in patients with prior pelvic surgery or radiation. Urodynamics may reveal detrusor overactivity, but up to 40% of patients with OAB have normal urodynamic findings.

Symptom Questionnaires

Validated symptom severity and quality-of-life tools such as the OAB-q and the International Consultation on Incontinence Questionnaire for OAB (ICIQ-OAB) are useful. The American Urological Association (AUA) Symptom Score (IPSS) is particularly helpful in men with concurrent voiding symptoms.

<image>Sample 3-day voiding diary demonstrating typical OAB pattern with high frequency, small voided volumes, urgency episodes, and urgency incontinence events</image>

First-Line Treatment: Behavioral Therapy

Behavioral Modifications

Behavioral therapy is the first-line treatment for OAB and includes several components. Fluid management involves reducing total intake to six to eight cups per day while avoiding caffeine, alcohol, and carbonated beverages that can irritate the bladder. Timed voiding schedules encourage patients to void every two to three hours to prevent bladder overfilling. Bladder training gradually increases voiding intervals by 15 to 30 minutes and incorporates urge suppression techniques. Urge suppression involves stopping activity, sitting down, performing pelvic floor contractions (squeezing), waiting for the urge to subside, and then walking to the bathroom. Pelvic floor muscle training strengthens the external sphincter and improves urgency control. Weight loss is also beneficial, as obesity is a shared risk factor with stress urinary incontinence. Behavioral therapy alone leads to improvement in 50-80% of patients.

Second-Line Treatment: Pharmacotherapy

Antimuscarinics (Anticholinergics)

Antimuscarinic agents work by blocking muscarinic (primarily M3) receptors on detrusor smooth muscle, thereby reducing involuntary contractions. They also act on muscarinic receptors in the urothelium and afferent nerves. Several drugs are available with varying selectivity and side effect profiles. Immediate-release (IR) oxybutynin at 5 mg two to three times daily is non-selective and associated with the highest side effects but is the cheapest option. Extended-release (ER) oxybutynin (5-30 mg daily) is better tolerated. Topical formulations of oxybutynin (gel or patch) provide lower systemic anticholinergic effects. Tolterodine, available as IR (2 mg twice daily) and ER (4 mg daily), is non-selective but better tolerated than oxybutynin IR. M3-selective agents such as solifenacin (5-10 mg daily) and darifenacin (7.5-15 mg daily) are effective; solifenacin commonly causes constipation, while darifenacin has minimal cognitive effects. Fesoterodine (4-8 mg daily) is a non-selective agent and an active metabolite of tolterodine. Trospium (20 mg twice daily or 60 mg ER daily) is a non-selective quaternary amine that does not cross the blood-brain barrier, making it safer for patients with cognitive concerns.

Antimuscarinic Side Effects

Common side effects of antimuscarinics include dry mouth, affecting 20-30% of patients, constipation in 10-15%, blurred vision, and cognitive impairment particularly in elderly patients, manifesting as memory problems, confusion, or delirium. Tachycardia and rare urinary retention can also occur; therefore, post-void residual should be checked in high-risk patients. Contraindications include uncontrolled narrow-angle glaucoma, urinary retention, and gastric retention.

Anticholinergic Cognitive Burden

Cognitive side effects are a major concern in elderly patients over 65 years old. Cumulative anticholinergic exposure has been associated with an increased risk of dementia, as demonstrated by Gray et al. in a 2015 JAMA Internal Medicine study. The AUA/SUFU guidelines recommend avoiding antimuscarinics in elderly patients with cognitive impairment and exercising caution in those over 65. When antimuscarinics are necessary in elderly patients, trospium is preferred due to its quaternary amine structure that prevents crossing the blood-brain barrier, or darifenacin due to its M3 selectivity and minimal central nervous system effects. Beta-3 agonists are preferred as first-line pharmacotherapy in this population.

Beta-3 Adrenergic Agonist

Mirabegron (Myrbetriq), dosed at 25-50 mg daily, activates beta-3 adrenergic receptors on detrusor smooth muscle, promoting relaxation during bladder filling. Its efficacy is comparable to antimuscarinics but without anticholinergic side effects or cognitive impairment. Side effects include hypertension, which requires blood pressure monitoring, urinary tract infections, headache, and nasopharyngitis. It is contraindicated in patients with uncontrolled hypertension (blood pressure >180/110 mmHg). Vibegron (Gemtesa), a newer beta-3 agonist dosed at 75 mg daily, does not inhibit CYP2D6, resulting in fewer drug interactions compared to mirabegron. It has comparable efficacy and has not been associated with clinically significant blood pressure elevation in clinical trials.

Combination Therapy

Combination therapy with an antimuscarinic and a beta-3 agonist provides additive benefits when monotherapy is insufficient. The SYNERGY trial demonstrated that solifenacin plus mirabegron is superior to either agent alone. The AUA guideline supports combination therapy as an option before proceeding to third-line treatments. However, clinicians should monitor for increased anticholinergic burden with combination use.

<image>Mechanism of action diagrams for antimuscarinic agents (blocking M3 receptors on detrusor) and beta-3 agonists (activating beta-3 receptors for detrusor relaxation) in the treatment of OAB</image>

Topical Estrogen

Vaginal estrogen, available as cream, ring, or tablet, is beneficial for postmenopausal women with OAB, particularly when symptoms are related to vaginal atrophy. It serves as adjunctive therapy rather than a standalone treatment. Systemic estrogen, however, may worsen urinary symptoms and should not be used for OAB.

Treatment Algorithm (AUA/SUFU 2019)

The recommended treatment algorithm begins with behavioral therapy for all patients as first-line management. Second-line treatment involves pharmacotherapy with either an antimuscarinic or a beta-3 agonist, combined with continued behavioral therapy. If monotherapy fails, combination therapy or switching medication classes is advised. Third-line therapies include onabotulinumtoxinA injections, sacral neuromodulation, or percutaneous tibial nerve stimulation (PTNS), which are covered separately.

Monitoring and Follow-Up

Response to medication should be assessed at four to eight weeks after initiation, using voiding diaries and symptom questionnaires for objective evaluation. If there is no benefit at an adequate dose after eight to twelve weeks, medication should be switched or escalated. Post-void residual volume should be monitored if anticholinergic side effects or retention symptoms develop. In elderly patients, cognitive function should be monitored with tools such as the Mini-Mental State Examination (MMSE) or Montreal Cognitive Assessment (MoCA) at baseline and follow-up. Blood pressure should be monitored long-term in patients receiving beta-3 agonists.

Clinical Pearls

Overactive bladder is a clinical diagnosis based on symptoms, and urodynamic studies are not required for initial management. Behavioral therapy is the cornerstone of treatment and should be maintained even when pharmacotherapy is added. In elderly patients over 65, beta-3 agonists such as mirabegron or vibegron should be the first-line pharmacologic agents to avoid the cognitive burden associated with anticholinergics. If an antimuscarinic is necessary in this population, trospium is preferred due to its inability to cross the blood-brain barrier. The voiding diary remains the most valuable tool for diagnosis and monitoring treatment response. In men presenting with OAB symptoms, concurrent bladder outlet obstruction from BPH should always be considered, and post-void residual measurement is essential before starting antimuscarinics to mitigate the risk of urinary retention. Combination therapy with an antimuscarinic and beta-3 agonist is an evidence-based step before advancing to third-line invasive therapies.

References

• AUA/SUFU Guideline on Diagnosis and Treatment of Overactive Bladder, 2019 (amended 2023)
• EAU Guidelines on Urinary Incontinence, 2024 Update
• Gormley EA, et al. "Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline." J Urol. 2019.
• Gray SL, et al. "Cumulative use of strong anticholinergics and incident dementia." JAMA Intern Med. 2015;175(3):401-407.
• Herschorn S, et al. "Efficacy and safety of combinations of mirabegron and solifenacin" (SYNERGY Trial). Eur Urol. 2017.
• Campbell-Walsh-Wein Urology, 12th Edition, Chapter on Overactive Bladder

Read this lecture as Markdown